Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressive therapy in strictly selected low/intermediate-risk myelodysplastic syndrome
ChiCTR-TNC-11001512Phase 4Completed
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Aug 2006
- Modality
- Small Molecules, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin and cyclosporine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: duration of response, disease progression rate and 4 more. Started Aug 2006; status: completed.
02
Drugs
antithymocyte globulincyclosporine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-TNC-11001512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-11001512.